Revenue - Licensing, Royalties, and Other (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Apr. 29, 2025	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Revenue Recognition
Total revenue		$ 239,240	$ 415,484	$ 905,895	$ 509,339
Takeda
Revenue Recognition
Upfront payments		14,500		14,500
Unrecongnized consideration	$ 4,000
Licensing, royalties, and other
Revenue Recognition
Total revenue		228,516	392,896	273,493	396,915
Database lock of an Existing Phase 2/3 clinical trial
Revenue Recognition
Upfront fee and milestones		500,000
Milestone payments for database lock		50,000
Sanofi \| Upfront fee
Revenue Recognition
Total revenue		0	386,250	0	386,250
Sanofi \| Milestones
Revenue Recognition
Total revenue		175,000	0	175,000	0
Sanofi \| Upfront fee amortization
Revenue Recognition
Total revenue		12,268	4,573	32,180	4,573
Sanofi \| Milestones amortization
Revenue Recognition
Total revenue		5,665	2,073	14,808	2,073
Sanofi \| Cost reimbursements
Revenue Recognition
Total revenue		6,479	0	17,745	0
Sanofi \| Licensing, royalties, and other
Revenue Recognition
Total revenue		199,412	392,896	239,733	392,896
Takeda \| Upfront fee
Revenue Recognition
Total revenue		18,500	0	18,500	0
Takeda \| Milestones
Revenue Recognition
Total revenue		3,434	0	3,434	0
Takeda \| Royalties
Revenue Recognition
Total revenue		5,000	0	5,000	0
Takeda \| Support services
Revenue Recognition
Total revenue		278	0	278	0
Takeda \| Licensing, royalties, and other
Revenue Recognition
Total revenue		27,212	0	27,212	0
Other partners \| Licensing, royalties, and other
Revenue Recognition
Total revenue		$ 1,892	$ 0	$ 6,548	$ 4,019